Chemoradiotherapy for Treatment of Esophageal Cancer in Japan: Current Status and Perspectives

Por Shitara, Kohei, Muro, Kei
Publicado em 2009

Was the Unexpected Result a Response to Reintroduction of Effective Chemotherapy?

Por Shitara, Kohei, Muro, Kei
Publicado em 2009

No benefit from ramucirumab in first-line chemotherapy?

Por Mitani, Seiichiro, Muro, Kei
Publicado no Transl Gastroenterol Hepatol (2017)

Is ramucirumab and paclitaxel therapy beneficial for second-line treatment of metastatic gastric or junctional adenocarcinoma for patients with ascites? Analysis of RAINBOW phase 3...

Por Muro, Kei, Jen, Min-Hua, Cheng, Rebecca
Publicado no Cancer Manag Res (2019)

Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data

Por Muro, Kei, Salinardi, Taylor, Singh, Arvind Rup, Macarulla, Teresa
Publicado no Cancers (Basel) (2020)

Durable Response of Human Epidermal Growth Factor Receptor-2-Positive Gastric Adenosquamous Carcinoma to Trastuzumab-Based Chemotherapy

Por Kadowaki, Shigenori, Yatabe, Yasushi, Nitta, Sohei, Ito, Yuichi, Muro, Kei
Publicado em 2014

Pseudocirrhosis in Gastric Cancer with Diffuse Liver Metastases after a Dramatic Response to Chemotherapy

Por Mitani, Seiichiro, Kadowaki, Shigenori, Taniguchi, Hiroya, Muto, Hisanori, Muro, Kei
Publicado no Case Rep Oncol (2016)

Combination of Oxaliplatin and 5-Fluorouracil/Leucovorin for Advanced Esophageal Squamous Cell Carcinoma Refractory or Intolerant to Standard Therapies

Por Mitani, Seiichiro, Kadowaki, Shigenori, Kato, Kyoko, Masuishi, Toshiki, Muro, Kei
Publicado no Case Rep Oncol (2019)

FOLFIRI Plus Bevacizumab 5 mg/kg Versus 10 mg/kg as Second-line Therapy in Patients with Metastatic Colorectal Cancer Who Have Failed First-line Bevacizumab Plus Oxaliplatin-based...

Por Mishima, Hideyuki, Oba, Koji, Sakamoto, Junichi, Muro, Kei, Yoshino, Takayuki, Hyodo, Ichinosuke, Maehara, Yoshihiko
Publicado em 2012

Complete Response to Trastuzumab-Based Chemotherapy in a Patient with Human Epidermal Growth Factor Receptor-2-Positive Metastatic Salivary Duct Carcinoma ex Pleomorphic Adenoma

Por Kadowaki, Shigenori, Yatabe, Yasushi, Hirakawa, Hitoshi, Komori, Azusa, Kondoh, Chihiro, Hasegawa, Yasuhisa, Muro, Kei
Publicado em 2013

Cetuximab plus FOLFOX for Patients with Metastatic Colorectal Cancer with Poor Performance Status and/or Severe Tumor-Related Complications

Por Shitara, Kohei, Yokota, Tomoya, Takahari, Daisuke, Shibata, Takashi, Sato, Yozo, Tajika, Masahiro, Ura, Takashi, Muro, Kei
Publicado em 2010

Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer

Por Boku, Narikazu, Muro, Kei, Machida, Nozomu, Hashigaki, Satoshi, Kimura, Nobuyuki, Suzuki, Mie, Lechuga, Mariajose, Miyata, Yoshinori
Publicado em 2013

Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to f...

Por Hirata, Kenro, Hamamoto, Yasuo, Ando, Masahiko, Imamura, Chiyo K., Yoshimura, Kenichi, Yamazaki, Kentaro, Hironaka, Shuichi, Muro, Kei
Publicado no BMC Cancer (2020)

Trastuzumab for a Patient With Heavily Pretreated Gastric Cancer Plus Massive Ascites and Ovarian Metastasis

Por Shitara, Kohei, Yatabe, Yasushi, Yokota, Tomoya, Takahari, Daisuke, Shibata, Takashi, Ura, Takashi, Satoh, Yozo, Kodera, Yasuhiro, Muro, Kei
Publicado em 2012

Efficacy of palliative radiotherapy for gastric bleeding in patients with unresectable advanced gastric cancer: a retrospective cohort study

Por Kondoh, Chihiro, Shitara, Kohei, Nomura, Motoo, Takahari, Daisuke, Ura, Takashi, Tachibana, Hiroyuki, Tomita, Natsuo, Kodaira, Takeshi, Muro, Kei
Publicado no BMC Palliat Care (2015)

A multicenter single-arm Phase II clinical trial of second-line FOLFIRI plus panitumumab after first-line treatment with FOLFOX plus panitumumab for initial RAS wild-type colorecta...

Por Maeda, Hiromichi, Nagata, Naoki, Nagasaka, Takeshi, Oba, Koji, Mishima, Hideyuki, Kato, Takeshi, Yoshida, Kazuhiro, Muro, Kei, Sakamoto, Junichi
Publicado no Oncol Lett (2019)

Observational study of first-line chemotherapy including cetuximab in patients with metastatic colorectal cancer: CORAL trial

Por Muro, Kei, Itabashi, Michio, Hashida, Hiroki, Masuishi, Toshiki, Bando, Hiroyuki, Denda, Tadamichi, Yamanaka, Takeharu, Ohashi, Yasuo, Sugihara, Kenichi
Publicado no Jpn J Clin Oncol (2019)

Pertuzumab plus trastuzumab and chemotherapy for Japanese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subgroup analysis of the JACOB trial

Por Shitara, Kohei, Hara, Hiroki, Yoshikawa, Takaki, Fujitani, Kazumasa, Nishina, Tomohiro, Hosokawa, Ayumu, Asakawa, Takashi, Kawakami, Satoe, Muro, Kei
Publicado no Int J Clin Oncol (2019)

Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer

Por Sasaki, Yasutsuna, Nishina, Tomohiro, Yasui, Hirofumi, Goto, Masahiro, Muro, Kei, Tsuji, Akihito, Koizumi, Wasaburo, Toh, Yasushi, Hara, Takuo, Miyata, Yoshinori
Publicado no Cancer Sci (2014)

Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients11

Por Taniguchi, Hiroya, Yamazaki, Kentaro, Yoshino, Takayuki, Muro, Kei, Yatabe, Yasushi, Watanabe, Toshiaki, Ebi, Hiromichi, Ochiai, Atsushi, Baba, Eishi, Tsuchihara, Katsuya
Publicado no Cancer Sci (2015)